Evaluation of Tp-e Interval and Tp-e/QT Ratio in Dermatomyositis and Analysis of Their Relationship With Inflammation
- Conditions
- InflammationDermatomyositisMyocardial Repolarization
- Interventions
- Other: disease
- Registration Number
- NCT06002750
- Lead Sponsor
- The Third People's Hospital of Hangzhou
- Brief Summary
The goal of this observational study is to investigate ventricular repolarization utilizing Tp-e intervals and Tp-e/QT ratios in patients with DM. The main questions it aims to answer are:
* 1.Exploring the changes in ventricular repolarization parameters (QT interval, QTc interval, QTd, Tp-e interval, Tp-e/QT ratio) in patients with dermatomyositis, providing quantifiable indicators for early detection of arrhythmia in dermatomyositis patients;
* 2.Exploring the role of inflammation in ventricular repolarization in DM patients, providing a basis for in-depth research on the diagnosis and prevention of arrhythmia in DM patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Regardless of gender, registered residence and education level, voluntarily participate in this study and sign the informed consent form.
Clinical diagnosis of Dermatomyositis.
Previous history of heart disease (such as myocardial infarction, cardiac pacing, congenital heart disease, ischemic heart disease, etc.), chronic kidney disease, etc; Patients with other connective tissue diseases; Pregnant and lactating women.
Taking drugs that affect electrocardiogram indicators, such as macrolides, quinolones, quinidine, amiodarone, antipsychotic drugs, etc.
Patients with severe lack of case data.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Dermatomyositis patients disease -
- Primary Outcome Measures
Name Time Method the Tp-e interval and Tp-e/QT ratio were positively correlated with Inflammation. November 2011 to November 2022 QTc, Tp-e interval, and Tp-e/QT ratio were increased in DM patients. November 2011 to November 2022
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
The Third People's Hospital of Hangzhou
🇨🇳Zhejiang, Hangzhou, China